Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 167,291

Document Document Title
WO/2018/127914A1
The present invention provides compositions and methods for the treatment of Sjogren's syndrome (SS) and SS-related symptoms in human subjects by synthetic peptides based on the sequence of CDR1 of an anti-DNA monoclonal antibody.  
WO/2018/124180A1
The present invention addresses the problem of providing an antitumor agent that is exceptional as a treatment agent for the prevention and/or treatment of tumors involving bromodomains, and providing a bromodomain inhibitor that is usef...  
WO/2018/122409A1
Compositions including an fatty acid, such as an odd chain fatty acid or a very long even chain fatty acid, and salts and derivatives thereof, and methods for treatment and prophylaxis of conditions related to inflammation and conditions...  
WO/2018/124283A1
The present invention addresses the problem of providing a solid pharmaceutical composition that suppresses the bitter taste characteristic of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof and has excellent ...  
WO/2018/124282A1
The present invention addresses the problem of providing a pharmaceutical composition that contains a high concentration of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof and masks the bitter taste thereof, a...  
WO/2018/125746A1
The present invention relates to 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells, including inducing the stem/progenitor cells to proliferate while maintaining, in the d...  
WO/2018/124284A1
The present invention addresses the problem of providing a solid pharmaceutical composition that suppresses both the bitter taste and the bitter aftertaste of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof. T...  
WO/2018/124001A1
The present invention pertains to novel, exceptional low-molecular compounds that specifically antagonize the BMP signaling pathway, and because these compounds can be used to modulate cell growth, differentiation, proliferation, and apo...  
WO/2018/122746A1
The application is directed to compounds of formula (I) : (I), and formula (IA): (IA) and their salts and solvates, wherein R1, R2, R3, R4, R5, n, A1, A2, A3, and Y are as set forth in the specification, as well as to a method for their ...  
WO/2018/123828A1
The present invention provides a fermented product obtained by fermenting honey and chamomile or a processed product thereof, by using Lactobacillus kunkeei.  
WO/2018/123920A1
Provided are: a compound that exhibits a broad antibacterial spectrum against various bacteria, including gram-negative bacteria; and a pharmaceutical composition that has antibacterial activity against carbapenem-resistant bacteria.  
WO/2018/124236A1
Provided is a medicinal composition to be used for treating an intractable heart tissue fibrosis disease accompanying chronic heart failure. The medicinal composition, which is to be used for treating an intractable heart tissue fibrosis...  
WO/2018/124009A1
The purpose of the present invention is to provide a prophylactic or ameliorating agent for hypothermia which is effective against hypothermia. Specifically provided is a prophylactic or ameliorating agent for hypothermia which compris...  
WO/2018/123908A1
[Problem] An objective of the present invention is to provide a novel composition that can inhibit the activity of PDE5. [Solution] A composition for inhibiting phosphodiesterase-5 activity, the composition comprising a processed product...  
WO/2018/124002A1
The purpose of the present invention is to provide: a composition for protein L-isoaspartate methyltransferase (PIMT) activation with which it is possible to activate PIMT; a novel indicator for evaluating skin restoration or repair acti...  
WO/2018/125598A1
Compositions and methods for selectively and permanently removing hair from the body. The compositions are formulated to be topically applied upon discrete areas of the body and contain an agent present in an amount sufficient to cause p...  
WO/2018/123628A1
The present invention addresses the issue of providing a cell pharmaceutical composition capable of maintaining a cell state well and a high survival rate over the long term. This cell pharmaceutical composition contains cells (A) and a ...  
WO/2018/117249A1
An oral ibuprofen preparation which includes ibuprofen, magnesium oxide, and glycyrrhetinic acid and which is highly effective in mitigating the gastric-mucosa-disordering action of ibuprofen. Specifically, the oral ibuprofen preparation...  
WO/2018/114988A1
The present invention relates to the medical field, in particular to the enhancement of brain performances and to the treatment of pathological stress. More specifically the present invention relates to a nanoparticle or nanoparticles' a...  
WO/2018/117177A1
The present invention relates to a Brk inhibitor compound represented by general formula (I) (wherein all the symbols are as defined in the description), a salt of the compound, an N-oxide of the compound, a solvate of the compound, or a...  
WO/2018/116178A1
The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharm...  
WO/2018/117127A1
Provided is a compound represented by formula (1), said compound exhibiting an effect of inhibiting cancer cell sphere formation ability and being useful as an agent for removing iPS cells, or a salt thereof. [In formula (1): ring Q1 rep...  
WO/2018/114309A1
This invention relates generally to methods and compositions for the treatment or prevention of critical illness myopathy and critical illness polyneuropathy and of critical illness myopathy and critical illness polyneuropathy caused by ...  
WO/2018/117151A1
The present invention relates to: a method for producing a 7H-pyrrolo[2,3-d]pyrimidine derivative which is useful as a Janus kinase (JAK) inhibitor; a cocrystal of the derivative; a method for producing the cocrystal; and a method for pu...  
WO/2018/117244A1
Provided is a novel peptide that includes an amino acid sequence indicated by SEQ ID NO: 30, and inhibits protease activity.  
WO/2018/117237A1
The present invention provides: a novel antibody capable of binding to human CD3; or a molecule which is capable of binding to an antigen and contains the antibody. Provided are: a novel antibody capable of binding to human CD3; a molecu...  
WO/2018/119039A1
The present invention relates to the compound of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof. The present invention is further concerned with the use of such a compound or salt, stereoisomer, tautomer or N-oxide t...  
WO/2018/110515A1
A pharmaceutical composition and a treatment method, each of which is characterized in that an antibody-drug conjugate and an immune checkpoint inhibitor are administered in combination, wherein the antibody-drug conjugate is formed by b...  
WO/2018/110654A1
Provided is an undifferentiated stem cell removal agent contains at least one component selected from the group consisting of the following (a) to (d): (a) cells that can specifically inhibit the propagation of glypican-3-expressing cell...  
WO/2018/109188A1
The invention relates to a compound of formula (I), as described in the invention, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, or a mixture thereof for use in the prevention and/or treatment of X-ALD. The inv...  
WO/2018/107415A1
The present invention relates to a compound represented by formula (I) : and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disor...  
WO/2018/110686A1
The present invention provides a pharmaceutical composition for healing tissue, said pharmaceutical composition containing: adherent cells originating from mesenchymal tissue that has been treated with a physiologically active polypeptid...  
WO/2018/103663A1
Provided in the present invention are a substituted pyrazinecarboxamide compound and a composition comprising the same and the use thereof. The substituted pyrazinecarboxamide compound is a pyrazinecarboxamide compound as represented by ...  
WO/2018/107148A1
Methods and compositions for tissue regeneration of the present invention include a biocompatible porous composite of a decellularized tissue and an aptamer- functionalized hydrogel, wherein the aptamers of the aptamer-functionalized hyd...  
WO/2018/106845A1
Compositions of glycan polymers and methods of making and manufacturing the same are described herein. Also provided are methods of treating a disease or disorder with a glycan polymer preparation.  
WO/2018/104950A1
The present invention provides a synergistic anti-inflammatory composition comprising one more anti-inflammatory agents such as a steroid, non-steroidal anti-inflammatory drug (NSAID) or a cannabinoid in combination with one or more sulf...  
WO/2018/107061A1
Provided herein are lipid-based nanoparticles (e.g., exosomes) having (a) a core comprising a cationic polymer and a therapeutic agent (e.g., a therapeutic protein, an antibody, an inhibitory RNA, and/or a small molecule drug) and (b) a ...  
WO/2018/106738A1
Described herein are macromonomers, conjugates comprising the macromonomers (also referred to alternatively as "BRUSH", or "BRUSH conjugates"), and brush arm star polymer particles comprising the conjugates (also referred to as "BASPs" o...  
WO/2018/104172A1
The present invention relates to compounds and method for treating and/or preventing Barth syndrome as well as methods for identifying such compounds. In particular, the invention concerns compounds that inhibit the cytosolic protein syn...  
WO/2018/105630A1
The present invention pertains to: a drug for preventing and/or treating cognitive dysfunction and/or a neurodegenerative disease accompanied by accumulation of prionoids, said drug comprising hemagglutinating virus of Japan envelope as ...  
WO/2018/100290A1
The invention relates to a compound of formula (I) in which R' and R'' are independently selected from: a hydrogen; the halogens; the alkyls, preferably with 1, 2 or 3 carbon atoms; and a –CO-R1 function in which R1 is an alkyl prefera...  
WO/2018/101470A1
The present invention provides an antibody to a fibrosis-related molecule and a medical application thereof. An antibody that binds to CHL1 protein and an antibody that neutralizes the binding of CHL1 protein to fibroblasts.  
WO/2018/101477A1
The present invention addresses the problem of providing an endocytosis enhancer comprising associates formed from a fluorescent protein. The fluorescent protein is preferably any one selected from the group consisting of a white fluores...  
WO/2018/101261A1
The present invention provides a prophylactic agent, an onset-suppressing agent or a therapeutic agent for progressive immune demyelinating diseases, which contains a substance capable of suppressing or inhibiting the production of prola...  
WO/2018/101434A1
The present invention addresses the problem of providing a glycosylated chlorin e6 derivative which has excellent tumor cell-killing properties (phototoxic property) and growth-inhibiting effect on tumor tissues and which is used for pho...  
WO/2018/101398A1
The present invention provides a pharmaceutical composition for use in the treatment or prevention of inflammatory bowel disease (IBD). More particularly, the present invention provides a pharmaceutical composition that contains apelin o...  
WO/2018/100143A1
The invention relates to a placental growth factor (PlGF) to be used as a drug in the prevention and/or treatment of fetal alcohol syndrome disorders (FASD) selected from the group comprising fetal alcohol syndrome (FAS), cerebrovascular...  
WO/2018/101329A1
The purpose of the present invention is to develop a therapeutic agent for inflammatory diseases such as inflammatory bowel disease and NASH, said therapeutic agent having few adverse effects and high efficacy. The present invention prov...  
WO/2018/101102A1
Provided are: a gastric inhibitory polypeptide elevation inhibitor that contains arabinoxylan as an active ingredient; and an agent for preventing or ameliorating stodgy feeling in the stomach.  
WO/2018/096100A1
The present invention provides a new use for cannabinoids in the prevention of pre-cachexia or cachexia in a patient suffering from cancer, wherein said cannabinoid is administered at low dosage and wherein administration is started prio...  

Matches 1 - 50 out of 167,291